Helen Burt

Add links
From Wikipedia, the free encyclopedia

Helen Mary Burt
Born
Manchester
Alma materUniversity of British Columbia
University of Bath
Scientific career
InstitutionsUniversity of British Columbia
ThesisEffect of crystal anisotropy and crystal defects on dissolution (1980)

Helen M. Burt OC is a British-Canadian pharmaceutical scientist who is the Angiotech Professor of Drug Delivery at the University of British Columbia. She serves as Associate Vice President of Research and Innovation at UBC. Her research considers novel therapeutics based on nanotechnology, including drug delivery systems for the treatment of bladder cancer and coronary artery disease.

Early life and education[edit]

Burt is from Manchester in the United Kingdom.[1][2] During a high school trip to a local hospital, she was first introduced to pharmacy.[3] Burt was an undergraduate student at the University of Bath, where she specialised in pharmacy. She moved to Canada to complete her graduate research as a doctoral student at the University of British Columbia, where she studied anisotropy and defects on dissolution of crystals.[4]

Research and career[edit]

Burt joined the faculty at the University of British Columbia in 1980.[5] Her research involves the use of nanotechnology for drug delivery. She has demonstrated that systems can provide targeted relief to different parts of the body, and release specific amounts of drug and controlled rates.[1] In particular, Burt has studied nanocrystalline cellulose, a molecular substrate that has large surfaces areas and negative surface charges. Nanocrystalline cellulose can withstand binding of high quantities of drugs, and contain hydroxyl groups that can be used for surface modification. The hydroxyl groups can be used to selective load and release treatments, including ant-infective agents in wound dressings.[6]

Burt worked alongside Sitka Biopharma on STK-01, a polymer nanoparticle based drug-delivery system that can be used to treat bladder cancer.[7][8] The drug, which delivers targeted chemotherapy (Docetaxel) to non-muscle invasive bladder cancer, entered clinical trials in 2017.[9][10]

Burt co-founded the Centre for Drug Research and Development in 2004. The centre later became adMare BioInnovations, which allows biomedical scientists to translate their research into industry. In 2011, Burt was made Associate Vice President of Research and Innovation.[1]

Awards and honours[edit]

Selected publications[edit]

Scholia has an author profile for Helen Burt.
  • Kevin Letchford; Helen Burt (23 November 2006). "A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes". European Journal of Pharmaceutics and Biopharmaceutics. 65 (3): 259–269. doi:10.1016/J.EJPB.2006.11.009. ISSN 0939-6411. PMID 17196803. Wikidata Q36695819.
  • John K Jackson; Kevin Letchford; Benjamin Z Wasserman; Lucy Ye; Wadood Y Hamad; Helen M Burt (10 February 2011). "The use of nanocrystalline cellulose for the binding and controlled release of drugs". International Journal of Nanomedicine. 6: 321–330. doi:10.2147/IJN.S16749. ISSN 1176-9114. PMC 3044185. PMID 21383857. Wikidata Q39579655.
  • Liggins RT; Hunter WL; Burt HM (1 December 1997). "Solid-state characterization of paclitaxel". Journal of Pharmaceutical Sciences. 86 (12): 1458–1463. doi:10.1021/JS9605226. ISSN 0022-3549. PMID 9423162. Wikidata Q74017423.

References[edit]

  1. ^ a b c "Helen M. Burt | Faculty of Pharmaceutical Sciences". pharmsci.ubc.ca. Retrieved 1 February 2021.
  2. ^ "Executive Biographies | UBC Research + Innovation". research.ubc.ca. Retrieved 1 February 2021.
  3. ^ a b "These are the Order of Canada recipients from B.C. in 2020". vancouversun. Retrieved 1 February 2021.
  4. ^ Burt, Helen Mary (1982). Effect of crystal anisotropy and crystal defects on dissolution (Thesis). Ottawa: National Library of Canada. OCLC 15885609.
  5. ^ "Alumni Profile: Dr. Helen Burt, PhD'80". Pharmsci. Retrieved 23 August 2023.
  6. ^ "Dr. Burt - Interview at CC-CRS". www.cc-crs.com. Retrieved 1 February 2021.
  7. ^ "CDRD Invests in Sitka Biopharma to Advance Bladder Cancer Treatment to Clinical Trial". www.businesswire.com. 11 February 2019. Retrieved 1 February 2021.
  8. ^ "Scientific Advisors". www.sitkabiopharma.com. Retrieved 1 February 2021.
  9. ^ "New bladder cancer therapy to start clinical trials". Cancer Research UK. 23 June 2017. Retrieved 1 February 2021.
  10. ^ "CDRD Invests in Sitka Biopharma to Advance Bladder Cancer Treatment to Clinical Trial". AP NEWS. 11 February 2019. Retrieved 1 February 2021.
  11. ^ Government of Canada, Natural Sciences and Engineering Research Council of Canada (28 June 2016). "NSERC - Synergy Awards for Innovation - Winners". Natural Sciences and Engineering Research Council of Canada (NSERC). Retrieved 1 February 2021.
  12. ^ "Award of Leadership Recipients". CSPS. Retrieved 1 February 2021.
  13. ^ "Faculty Research Award Winners | UBC Research + Innovation". research.ubc.ca. Retrieved 1 February 2021.
  14. ^ "UBC Pharm Sci professor Dr. Helen Burt appointed Officer of the Order of Canada | Faculty of Pharmaceutical Sciences". pharmsci.ubc.ca. Retrieved 1 February 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Helen_Burt&oldid=1188493595"